What Is GLP-1? Function, Effects and Research

GLP-1 is a gut-derived hormone that helps regulate blood glucose, insulin release, appetite and digestion.

Basics9 min read

Key takeaway

Glucagon-like peptide-1 (GLP-1) is an incretin hormone produced from the proglucagon precursor. Intestinal L-cells release it after nutrient intake. It increases glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying and influences appetite. GLP-1 medicines mimic or extend selected actions of this natural hormone.

At a glance

Article typeBasics
Main guideWhat is semaglutide? Structure, research and FDA status
Regulatory statusFDA-approved“It is an FDA-approved prescription drug (Ozempic, Wegovy, Rybelsus)” (Where to buy semaglutide)
ClassMetabolic & weight
Body systemsEndocrine & metabolism
Studies cited11 in this article · 62 across 18 articles on Semaglutide
ProductSemaglutide product page

What is GLP-1 is a common question in metabolic research because this hormone connects food intake with blood sugar regulation. Researchers first studied its natural role before developing medicines that activate its receptor.

Quick answer: GLP-1 stands for glucagon-like peptide-1. It is a hormone released mainly by specialized cells in the intestine after eating. It helps the body coordinate insulin and glucagon responses with incoming nutrients.

What does GLP-1 stand for?

GLP-1 means glucagon-like peptide-1. It is one of several biologically active peptides produced when the body processes proglucagon.

The proglucagon gene encodes a larger precursor protein. Different tissues process that precursor into different products. In intestinal L-cells, processing produces GLP-1 and other proglucagon-derived peptides.

The active forms studied most often include GLP-1(7-36) amide and GLP-1(7-37). Both can activate the GLP-1 receptor.

GLP-1 is not the same thing as a GLP-1 receptor agonist medicine. The hormone is naturally produced by the body. Medicines are engineered compounds that activate the same receptor or influence the pathway.

Who discovered GLP-1?

GLP-1 was first spotted in a gene sequence, not in blood. In 1983, Graeme Bell’s team decoded hamster preproglucagon. It held glucagon plus two glucagon-like peptides in tandem, and one of them is GLP-1 (Bell et al., 1983).

The finding mattered because of the incretin effect. Glucose absorbed from the gut triggers more insulin than an equal blood glucose rise produced without the gut. In a 1986 study, incretin factors accounted for about 73% of the insulin response in 8 healthy controls. In 14 people with type 2 diabetes, the figure was about 36% (Nauck et al., 1986).

In 1987, Svetlana Mojsov, Gordon Weir and Joel Habener tested synthetic GLP-1 on an isolated rat pancreas. GLP-1(7-37) raised insulin secretion 3- to 10-fold over baseline. The longer GLP-1(1-37) had no effect (Mojsov et al., 1987).

Jens Holst’s group in Copenhagen reported a similar result that year. Their truncated GLP-1 from pig intestine potently increased insulin secretion from an isolated pig pancreas (Holst et al., 1987).

A separate thread came from lizard venom. In 1992, John Eng’s team isolated exendin-4, a 39-amino-acid peptide, from the venom of the Gila monster (Eng et al., 1992). Its synthetic form, exenatide, is the first medicine in Table 2.

In 2024, Habener, Mojsov and Lotte Bjerre Knudsen of Novo Nordisk shared the Lasker~DeBakey Clinical Medical Research Award for GLP-1-based medicines. The foundation also credits Daniel Drucker, Holst, Nauck, Eng and others with key contributions (Lasker Foundation, 2024).

Where is GLP-1 produced?

GLP-1 is produced mainly by enteroendocrine L-cells in the intestinal lining. These cells respond to nutrients and signals from the digestive system.

GLP-1 is also produced in certain neurons in the brainstem. The intestinal and central nervous system sources contribute to different aspects of GLP-1 biology.

After nutrient intake, GLP-1 enters the circulation. Its active forms are rapidly broken down by the enzyme dipeptidyl peptidase-4 (DPP-4). This helps explain why natural GLP-1 has a short presence in circulation.

A human study found that circulating GLP-1 increased after oral glucose and a test breakfast. The researchers also observed increased insulin and reduced glucose and glucagon during experimental GLP-1 exposure. Read the human study.

What does GLP-1 do in the body?

GLP-1 has several connected effects. Its actions help coordinate blood glucose regulation with digestion and food intake.

Table 1

What does GLP-1 do in the body

Physiological actionWhat research has measured
Insulin secretionIncreases insulin release when glucose is elevated
Glucagon regulationSuppresses pancreatic glucagon secretion in relevant conditions
Gastric emptyingSlows the movement of stomach contents into the small intestine
Appetite signalingActs on gut-brain pathways involved in satiety and food intake
Glucose regulationHelps reduce post-meal blood glucose excursions

GLP-1's insulin effect is glucose-dependent. This means its insulin-stimulating action is stronger when blood glucose is elevated.

The hormone also reduces glucagon secretion in many physiological settings. Glucagon normally signals the liver to release stored glucose. This makes GLP-1 part of the body's coordinated response to meals.

How does GLP-1 affect insulin and blood sugar?

GLP-1 binds to the GLP-1 receptor on pancreatic beta cells. Receptor activation increases intracellular signaling that supports glucose-stimulated insulin secretion.

The receptor was cloned from rat pancreatic islets in 1992. It is 463 amino acids long, crosses the cell membrane seven times and is coupled to adenylate cyclase. Its sequence resembles only the receptors for secretin, calcitonin and parathyroid hormone (Thorens, 1992).

The receptor is not limited to the pancreas. A 2014 study of monkey and human tissue found it on pancreatic beta cells and in artery walls of the kidney and lung. It also appeared in the heart’s sinoatrial node and in parts of the stomach and gut. None was seen in primate liver or thyroid (Pyke et al., 2014). The Foundayo label adds that GLP-1 receptors are present in brain regions that regulate appetite.

Human experiments helped establish this role. In a study of healthy volunteers, GLP-1 increased insulin and lowered glucose and glucagon during controlled testing. The study identified GLP-1(7-36) amide as a physiological incretin. Read the study.

GLP-1 also affects pancreatic alpha cells and glucagon secretion. The overall response depends on glucose levels and physiological context.

This pathway is relevant to type 2 diabetes research. Studies have examined how GLP-1 signaling can improve glucose regulation when endogenous incretin activity is impaired.

How does GLP-1 affect appetite and digestion?

GLP-1 signaling influences appetite through communication between the gut and brain. Research implicates neural pathways that transmit information about nutrients and fullness.

GLP-1 also slows gastric emptying. This can change how quickly nutrients leave the stomach and enter the small intestine.

These effects are related but distinct. Gastric emptying concerns digestive movement. Appetite signaling concerns neural regulation of hunger and satiety.

Research into GLP-1 medicines examines both pathways. The relative contribution of each pathway can vary by molecule, exposure and clinical setting.

What is the difference between GLP-1 and GLP-1 medicines?

GLP-1 is a naturally occurring hormone. GLP-1 medicines are pharmaceutical compounds designed to activate the GLP-1 receptor or otherwise affect this biological pathway.

Some medicines have structures based on GLP-1. Others use different peptide sequences that still activate the receptor. Molecular changes can affect receptor activity, resistance to enzymatic breakdown and duration of action.

Not every medicine discussed alongside GLP-1 is a peptide. Orforglipron, for example, is a small-molecule GLP-1 receptor agonist. It is not a peptide. FDA approved it as Foundayo on April 1, 2026 (FDA announcement).

For an overview of approved products, see FDA-approved peptide medicines. For the broader class, see how GLP-1 receptor agonists work.

How do GLP-1 medicines outlast the natural hormone?

Natural GLP-1 is cleared within minutes. In a 2004 study of 10 healthy control subjects, intact GLP-1 had a plasma half-life of about 2.3 minutes. DPP-4 first cuts it to a shorter fragment, and the kidneys finish elimination (Meier et al., 2004).

Approved medicines get around this in a few ways. Some change the amino acid at position 8 to resist DPP-4. Some carry a fatty acid that binds albumin, a blood protein. Others are fused to albumin or to part of an antibody. Orforglipron is not a peptide at all.

Table 2

FDA-approved GLP-1 receptor agonists

MedicineUS brandsFirst US approvalHow the label describes the molecule
ExenatideByetta; Bydureon and Bydureon BCise (brand approvals withdrawn 2025 and 2026; a generic remains approved)2005Synthetic 39-amino-acid peptide first found in a lizard; partly overlaps the GLP-1 sequence
LiraglutideVictoza, Saxenda201097% homologous to human GLP-1, plus a C-16 fatty acid
AlbiglutideTanzeum (discontinued)2014Two modified GLP-1 copies fused to albumin; a glycine at position 8 resists DPP-4
DulaglutideTrulicity2014GLP-1 analog fused to a modified antibody (IgG4 Fc) fragment; DPP-4 site altered
LixisenatideAdlyxin2016Synthetic 44-amino-acid GLP-1 analogue
SemaglutideOzempic, Wegovy, Rybelsus201794% homologous to GLP-1; position 8 modified against DPP-4; C18 fatty diacid binds albumin
TirzepatideMounjaro, Zepbound2022Based on GIP; activates GIP and GLP-1 receptors; C20 fatty diacid binds albumin
OrforglipronFoundayo2026Small molecule, not a peptide; activates the human GLP-1 receptor

Approval years and discontinued status come from Drugs@FDA. Insulin combinations such as Xultophy and Soliqua are not listed. Rybelsus, approved in 2019, was the first GLP-1 pill. For two of these molecules side by side, see liraglutide vs. semaglutide.

What do GLP-1 medicine labels warn about?

The facts in this section come from FDA labels for approved medicines. Unapproved products, including research material, have no FDA-approved labeling.

Most of the common adverse reactions on these labels are digestive. The Ozempic label lists nausea, vomiting, diarrhea, abdominal pain and constipation, each in at least 5% of patients. The Mounjaro, Trulicity, Victoza and Foundayo labels list similar reactions.

The Ozempic, Victoza, Trulicity, Mounjaro and Foundayo labels carry a boxed warning about thyroid C-cell tumors in rodent studies. The Ozempic label says it is unknown whether semaglutide causes these tumors in humans.

Foundayo’s wording differs. Its label says orforglipron is not pharmacologically active in rats or mice and did not produce tumors in rodents. The Byetta and Adlyxin labels carry no boxed warning.

Other Ozempic label warnings include acute pancreatitis, gallbladder disease, low blood sugar with insulin or insulin secretagogues, and aspiration during anesthesia. In November 2026, FDA said it is requiring a class-wide warning about NAION, a rare eye condition (see FDA’s GLP-1 eye-risk warning).

Is GLP-1 the same as GIP?

No. GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) are separate incretin hormones.

GLP-1 is produced mainly by intestinal L-cells. GIP is produced mainly by intestinal K-cells. Both can stimulate glucose-dependent insulin secretion.

Their receptors and broader physiological effects differ. Some medicines target the GLP-1 receptor alone. Others are designed to activate both GLP-1 and GIP receptors.

See what is GIP for a separate explanation.

For more background, see Vitrapep’s GLP-1 class overview, semaglutide complete guide, semaglutide mechanism article, tirzepatide complete guide and what are peptides.

Frequently asked questions

Is GLP-1 a peptide?

Yes. GLP-1 is a peptide hormone derived from the larger proglucagon precursor.

Is GLP-1 naturally produced in the body?

Yes. Intestinal L-cells release GLP-1 in response to nutrients. Certain neurons also produce GLP-1.

Does GLP-1 increase insulin?

GLP-1 increases glucose-dependent insulin secretion. Its insulin-stimulating action is linked to the GLP-1 receptor on pancreatic beta cells.

Does GLP-1 slow digestion?

GLP-1 slows gastric emptying. This changes the rate at which stomach contents move into the small intestine.

Is semaglutide the same as GLP-1?

No. Semaglutide is a medicine that activates the GLP-1 receptor. It is not the natural GLP-1 hormone.

Is every GLP-1 receptor agonist a peptide?

No. Many are peptides, but orforglipron is a small molecule. It activates the GLP-1 receptor without being a peptide.

Who discovered GLP-1?

Several teams contributed in the 1980s. Svetlana Mojsov and Joel Habener showed that GLP-1(7-37) is an active insulin-releasing form, and Jens Holst’s group reported similar findings. Habener, Mojsov and Lotte Bjerre Knudsen shared the 2024 Lasker~DeBakey Clinical Medical Research Award.

How long does natural GLP-1 last in the blood?

Only minutes. A study in healthy volunteers measured a plasma half-life of about 2.3 minutes for intact GLP-1. The enzyme DPP-4 starts its breakdown.

What to know now

  • GLP-1 is a naturally occurring incretin hormone produced mainly by intestinal L-cells.
  • Its physiological actions include glucose-dependent insulin release, glucagon suppression, slower gastric emptying and appetite signaling.
  • GLP-1 medicines activate or influence this pathway, but they are not identical to the natural hormone.
  • Natural GLP-1 lasts only minutes in blood. Approved medicines resist breakdown through amino acid changes, albumin binding, protein fusion or a non-peptide design.

What we’re watching

  • Research into how gut-brain signaling contributes to GLP-1's effects on appetite.
  • New medicines that combine GLP-1 activity with other metabolic targets.
  • Further work separating the effects of gastric emptying, insulin secretion and central appetite pathways.

Also in the library

More for endocrine & metabolism

All 41 compounds for endocrine & metabolism

Sources: Kreymann 1987, The Lancet, 2; Edwards 1999, Diabetes, 48; Qualmann 1995, Acta Diabetologica, 32; Bell 1983, Nature, 302; Nauck 1986, Diabetologia, 29; Mojsov 1987, The Journal of Clinical Investigation, 79; Holst 1987, FEBS Letters, 211; Eng 1992, The Journal of Biological Chemistry, 267; Thorens 1992, Proceedings of the National Academy of Sciences of the United States of America, 89; Pyke 2014, Endocrinology, 155; Meier 2004, Diabetes, 53; Albert and Mary Lasker Foundation 2024, GLP-1-based therapy for obesity: 2024 Lasker~DeBakey Clinical Medical Research Award. All 12 citations

Back to the research library

References

  1. Kreymann, B., Williams, G., Ghatei, M. A., & Bloom, S. R. (1987). Glucagon-like peptide-1 7-36: A physiological incretin in man. The Lancet, 2(8571), 1300–1304. https://pubmed.ncbi.nlm.nih.gov/2890903/
  2. Edwards, C. M., Todd, J. F., Mahmoudi, M., Wang, Z., Wang, R. M., Ghatei, M. A., & Bloom, S. R. (1999). Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: Studies with the antagonist exendin 9-39. Diabetes, 48(1), 86–93. https://pubmed.ncbi.nlm.nih.gov/9892226/
  3. Qualmann, C., Nauck, M. A., Holst, J. J., Orskov, C., & Creutzfeldt, W. (1995). Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) [7-36 amide] in the fasting state in healthy subjects. Acta Diabetologica, 32(1), 13–16. https://pubmed.ncbi.nlm.nih.gov/7612912/
  4. Bell, G. I., Santerre, R. F., & Mullenbach, G. T. (1983). Hamster preproglucagon contains the sequence of glucagon and two related peptides. Nature, 302(5910), 716–718. https://pubmed.ncbi.nlm.nih.gov/6835407/
  5. Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986). Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia, 29(1), 46–52. https://pubmed.ncbi.nlm.nih.gov/3514343/
  6. Mojsov, S., Weir, G. C., & Habener, J. F. (1987). Insulinotropin: Glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. The Journal of Clinical Investigation, 79(2), 616–619. https://pubmed.ncbi.nlm.nih.gov/3543057/
  7. Holst, J. J., Orskov, C., Nielsen, O. V., & Schwartz, T. W. (1987). Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut. FEBS Letters, 211(2), 169–174. https://pubmed.ncbi.nlm.nih.gov/3542566/
  8. Eng, J., Kleinman, W. A., Singh, L., Singh, G., & Raufman, J. P. (1992). Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom: Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. The Journal of Biological Chemistry, 267(11), 7402–7405. https://pubmed.ncbi.nlm.nih.gov/1313797/
  9. Thorens, B. (1992). Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proceedings of the National Academy of Sciences of the United States of America, 89(18), 8641–8645. https://pubmed.ncbi.nlm.nih.gov/1326760/
  10. Pyke, C., Heller, R. S., Kirk, R. K., Ørskov, C., Reedtz-Runge, S., Kaastrup, P., Hvelplund, A., Bardram, L., Calatayud, D., & Knudsen, L. B. (2014). GLP-1 receptor localization in monkey and human tissue: Novel distribution revealed with extensively validated monoclonal antibody. Endocrinology, 155(4), 1280–1290. https://pubmed.ncbi.nlm.nih.gov/24467746/
  11. Meier, J. J., Nauck, M. A., Kranz, D., Holst, J. J., Deacon, C. F., Gaeckler, D., Schmidt, W. E., & Gallwitz, B. (2004). Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes, 53(3), 654–662. https://pubmed.ncbi.nlm.nih.gov/14988249/
  12. Albert and Mary Lasker Foundation. (2024). GLP-1-based therapy for obesity: 2024 Lasker~DeBakey Clinical Medical Research Award. Retrieved November 18, 2026, from https://laskerfoundation.org/winners/glp-1-based-therapy-for-obesity/